Advertisement
BMY vs GSK
Which Stock Would AI Choose? Bristol Myers Squibb (BMY) vs. GSK (GSK) Stock Comparison
Key Takeaways
- Bristol Myers Squibb (BMY) delivered full-year 2025 revenue of about $48.2 billion, with its Growth Portfolio up 17%, while GSK posted 2025 sales of roughly £32.7 billion, up 7% at constant exchange rates.
- Both companies are pivoting from aging legacy franchises toward newer specialty medicines, but BMY leans heavily on oncology and cardiovascular assets, while GSK is weighted toward HIV, respiratory/immunology, and vaccines.
- GSK has shown stronger recent price momentum and profit-margin expansion, whereas BMY trades at a lower valuation as it absorbs generic erosion in its Legacy Portfolio.
- Near-term catalysts differ: BMY is entering a "data-rich" year of pivotal readouts, while GSK is managing patent expiries and a CEO transition under new leadership.
- Risk profiles diverge — BMY carries concentration risk in a few blockbusters, and GSK faces vaccine policy headwinds and currency exposure.
- For more detail on each name, explore BMY Major News and BMY Today's Price Move, plus GSK Major News and GSK Today's Price Move.
- To see how automated systems are positioning across the market, visit the Trending AI Robots page.
Introduction
Bristol Myers Squibb and GSK are two global pharmaceutical leaders navigating similar industry forces — patent cliffs, pricing pressure, and the need to replenish pipelines — yet from different starting points. BMY is a U.S.-centric oncology and cardiovascular powerhouse working to offset generic erosion in its Legacy Portfolio, while GSK is a diversified British drugmaker focused on HIV, respiratory and immunology, and vaccines. This stock comparison is most relevant to healthcare-sector investors and traders weighing relative performance, growth durability, and valuation. The analysis below examines recent momentum, business-model contrasts, and how each name stacks up on observable market positioning.
BMY Overview and Recent Performance
Bristol Myers Squibb is a Princeton, New Jersey-based biopharmaceutical company with a portfolio concentrated in oncology, hematology, cardiovascular, and immunology. In its most recent quarterly results, BMY reported adjusted earnings per share (EPS) of $1.26, ahead of consensus, alongside full-year revenue of roughly $48.2 billion. The Growth Portfolio — including Opdivo, Reblozyl, Camzyos, Breyanzi, and newly launched Cobenfy — grew 17% to about $26.4 billion, while the Legacy Portfolio, pressured by generic competition for Revlimid, Pomalyst, and Sprycel, declined by double digits. Management raised its quarterly dividend to $0.63 per share, marking a 17th consecutive annual increase.
Sentiment in recent weeks has been supported by better-than-expected earnings and a strengthened balance sheet, though the stock's relative performance has lagged its large-cap pharma peer group over the prior six months. Analysts have maintained a broadly "Moderate Buy" stance, with recent price-target revisions reflecting cautious optimism. Key watchpoints include a pipeline of pivotal readouts expected through the back half of the year and the impact of U.S. Medicare Part D pricing changes on Eliquis, its top-selling drug.
GSK Overview and Recent Performance
GSK plc is a London-headquartered biopharma company organized around Specialty Medicines, Vaccines, and General Medicines. For full-year 2025, GSK reported sales of £32.7 billion, up 4% on a reported basis and 7% at constant exchange rates, with core EPS up 12%. Specialty Medicines led the way, growing 17%, with Oncology up 43%, HIV up 11%, and respiratory/immunology assets such as Nucala and Benlysta contributing double-digit gains. Vaccines rose a modest 2%, reflecting softer U.S. demand for Shingrix and Arexvy and competitive pressure in influenza.
Recent performance has been shaped by strong specialty-drug momentum, five major FDA approvals, and a leadership transition, with Luke Miels succeeding Emma Walmsley as CEO. The company also moved to deepen its oncology pipeline, including a roughly $10.6 billion agreement to acquire Nuvalent. Market sentiment has been generally favorable, with the stock outperforming several European peers over the past year. Watchpoints include upcoming patent expiries (such as the HIV drug Tivicay), vaccine-policy uncertainty in the U.S., and currency headwinds from a stronger pound sterling.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI trading bots, chosen from hundreds of automated strategies that collectively trade thousands of different tickers. Each bot operates with its own trading style, strategy, timeframe, performance history, and set of tickers it monitors, so only the strategies best suited to current market conditions earn a place in this featured section. The page highlights bots with measurable statistics — including win rates, trade frequency, and historical performance ranges — allowing traders to compare approaches at a glance. For those evaluating how automated systems interpret momentum and positioning in names like BMY and GSK, exploring the Trending AI Robots list is a practical starting point.
Head-to-Head Comparison
The two companies differ most clearly in therapeutic mix and geographic exposure. BMY derives a large share of sales from the U.S. and is heavily concentrated in oncology and cardiovascular medicine, giving it a higher dependence on a handful of blockbusters but also a deep, catalyst-rich late-stage pipeline. GSK is more diversified across HIV, vaccines, respiratory/immunology, and oncology, with broader international revenue and a steadier, if slower-growing, top line.
On momentum, GSK has demonstrated stronger relative performance and expanding core margins, while BMY trades at a discount to its peer group as the market weighs generic erosion against pipeline optionality. Risk factors also contrast: BMY faces concentration and Medicare pricing pressures on Eliquis, whereas GSK confronts patent expiries, vaccine-demand softness, and currency translation risk. In growth drivers, BMY leans on new launches and clinical readouts, while GSK emphasizes HIV durability, specialty ramp, and pipeline depth.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely lean toward GSK in the current environment. The company's more consistent trend, expanding core profitability, and diversified revenue base offer relatively steadier momentum than BMY's more binary, catalyst-dependent profile. That said, BMY presents a potentially stronger valuation case and a dense pipeline of near-term readouts that could shift positioning quickly. The outcome is probabilistic rather than fixed, and relative positioning may evolve as new data, pricing dynamics, and leadership decisions unfold.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Buy and GSK is a Buy.
Aroon Indicator for BMY shows an upward move is likely
BMY's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 217 similar instances where the Aroon Indicator showed a similar pattern. In 147 of the 217 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Indicator exited the oversold zone, 11 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 37%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMY as a result. In 51 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on October 16, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in 29 of 50 cases over the following month. The odds of a continued upward trend are 58%.
BMY moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BMY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +1.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 175 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 68 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
BMY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.687) is normal, around the industry mean (-1.421). P/E Ratio (13.627) is within average values for comparable stocks, (21.700). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.038) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
GSK's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for GSK moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 15 of the 23 cases the stock moved higher. This puts the odds of a move higher at 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on GSK as a result. In 48 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 04, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 29 of 46 cases over the following month. The odds of a continued upward trend are 63%.
GSK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 145 of 258 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.421). P/E Ratio (20.988) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.035) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
BMY | GSK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 73 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 67 | 37 | |
SMR RATING 1..100 | 22 | 34 | |
PRICE GROWTH RATING 1..100 | 43 | 46 | |
P/E GROWTH RATING 1..100 | 63 | 9 | |
SEASONALITY SCORE 1..100 | 65 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (81) in the Pharmaceuticals Major industry is in the same range as BMY (96). This means that GSK’s stock grew similarly to BMY’s over the last 12 months.
GSK's Profit vs Risk Rating (37) in the Pharmaceuticals Major industry is in the same range as BMY (67). This means that GSK’s stock grew similarly to BMY’s over the last 12 months.
BMY's SMR Rating (22) in the Pharmaceuticals Major industry is in the same range as GSK (34). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
BMY's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as GSK (46). This means that BMY’s stock grew similarly to GSK’s over the last 12 months.
GSK's P/E Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for BMY (63). This means that GSK’s stock grew somewhat faster than BMY’s over the last 12 months.
| BMY | GSK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 37% | 7 days ago 65% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 40% |
| Momentum ODDS (%) | 1 day ago 56% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 58% | 1 day ago 63% |
| TrendWeek ODDS (%) | 1 day ago 55% | 1 day ago 55% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 58% |
| Advances ODDS (%) | 1 day ago 57% | 28 days ago 63% |
| Declines ODDS (%) | 7 days ago 55% | 1 day ago 55% |
| BollingerBands ODDS (%) | 1 day ago 57% | 1 day ago 42% |
| Aroon ODDS (%) | 1 day ago 68% | 1 day ago 56% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while GSK’s FA Score has 1 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- GSK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 7 TA indicator(s) are bullish while GSK’s TA Score has 7 bullish TA indicator(s).
- BMY’s TA Score: 7 bullish, 3 bearish.
- GSK’s TA Score: 7 bullish, 3 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -1.99% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.44%. For the same industry, the average monthly price growth was +4.52%, and the average quarterly price growth was +7.13%.
Reported Earning Dates
BMY is expected to report earnings on Feb 04, 2027.
GSK is expected to report earnings on Feb 03, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+1.44% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.